Bayer announced today initiation of a Phase I clinical trial with BAY3498264, an investigational oral selective Son of Sevenless Homologue 1 (SOS1) inhibitor. The open-label, first-in-human, dose ...
Bayer initiates phase I study with SOS1 inhibitor, BAY3498264 in patients with advanced KRAS-mutated tumours: Berlin Saturday, December 14, 2024, 13:00 Hrs [IST] Bayer announced i ...
Bayer MaterialScience (D-51368 Leverkusen; www.bayermaterialscience.com) and thermoplastic elastomers specialist PTS Plastic Technologie Service (D-91587 Adelshofen; www.pts-marketing.de), are to ...